Annual report pursuant to Section 13 and 15(d)

Stockholder's Equity (Details Narrative)

v3.21.1
Stockholder's Equity (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Nov. 17, 2020
Aug. 17, 2020
Aug. 17, 2020
Apr. 02, 2020
Apr. 02, 2020
Feb. 07, 2020
Mar. 31, 2020
Jul. 31, 2019
Dec. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2016
May 04, 2017
Mar. 26, 2013
Warrant to purchase common stock                         1,199,978  
Loss on extinguishment                   $ (11,808,111)      
Outstanding debt obligations                         $ 6,000,000 $ 4,082,636
Common stock, par value                 $ 0.0001 $ 0.0001 $ 0.0001      
Warrants price                         $ 0.50  
Warrants exercised         $ 935,000         $ 105,089      
True-Up Payment [Member]                            
Number of warrants issued to purchase common stock   134,000 134,000                      
Warrant exercisable per share   $ 1.25 $ 1.25                      
Warrant expiration date     Aug. 31, 2025                      
Warrants value   $ 28,060 $ 28,060                      
Chanticleer Holdings, Inc [Member] | 2014 Stock Incentive Plan [Member]                            
Stock options granted                   400,010        
Warrants price             $ 0.50              
Deemed dividend             $ 325,000              
Warrants exercised             $ 1,200,000              
Sonnet BioTherapeutics, Inc [Member]                            
Subscription price       $ 0.01 $ 0.01                  
Sale of stock, number of shares 100                          
Number of warrants issued to purchase common stock       186,161 186,161                  
Sonnet BioTherapeutics, Inc [Member] | 2014 Stock Incentive Plan [Member]                            
Warrants price       $ 1.25 $ 1.25                  
Warrants exercised       $ 350,000                    
Redeemed warrants, shares       261,050                    
Redeemed warrants, value       $ 66,900                    
Warrants remained shares       525,554                    
Convertible note agreement percentage       10.00%                    
Warrant issued description       Additionally, 3,275,200 warrants were issued of which 2,925,200 warrants were issued with an exercise price ranging between $.125 and $.5 in connection with the issuance of the Company's 10% convertible note agreement and 350,000 warrants with an exercise price of $.125 were issued to the Company's bridge financing investor.                    
Maximum [Member]                            
Outstanding debt obligations                           $ 480,000
Maximum [Member] | Chanticleer Holdings, Inc [Member] | 2014 Stock Incentive Plan [Member]                            
Stock price volatility             95.00%              
Risk-free interest rates             84.00%              
Weighted average term             8 years              
Maximum [Member] | Sonnet BioTherapeutics, Inc [Member] | 2014 Stock Incentive Plan [Member]                            
Warrants price       $ 0.5 0.5                  
Minimum [Member] | Chanticleer Holdings, Inc [Member] | 2014 Stock Incentive Plan [Member]                            
Stock price volatility             88.00%              
Risk-free interest rates             1.70%              
Weighted average term             6 years 6 months              
Minimum [Member] | Sonnet BioTherapeutics, Inc [Member] | 2014 Stock Incentive Plan [Member]                            
Warrants price       $ 1.25 $ 1.25                  
2019 Rights Offering [Member]                            
Subscription price                     $ 1.00      
Common stock were issued               1,894,311            
Subscription shares               $ 4,190,524            
Gross proceeds from rights offering               6,009,733            
Outstanding debt obligations               3,075,000            
Remaining proceeds from the rights offering               $ 2,700,000            
2019 Rights Offering [Member] | Chardan Capital Markets, LLC and The Oak Ridge Financial Services Group Inc [Member]                            
Percentage of gross proceeds of rights offering               7.00%            
Reimburse expenses               $ 75,000            
Sales commission               286,000            
2019 Rights Offering [Member] | Maximum [Member]                            
Subscription shares               $ 6,084,733            
2020 Bridge Financing [Member]                            
Fair value of the derivative liability                 $ 184,800 $ 184,800        
Conversion price                 $ 0.50 $ 0.50        
9% Redeemable Series 1 Preferred Stock [member]                            
Redeemable preferred stock offering rights description                       The Company conducted a rights offering of units, each unit consisting of one share of 9% Redeemable Series 1 Preferred Stock ("Series 1 Preferred") and one Series 1 Warrant ("Series 1 Warrant") to purchase 10 shares of common stock.    
Warrant to purchase common stock                       10    
Preferred unit dividends                   37,518 77,975      
Redemption price                       $ 0.50    
Loss on extinguishment                   $ 161,900        
Convertible Preferred Stock: Series 2 [Member]                            
Preferred stock, par value                 $ 1,000 $ 1,000 $ 1,000      
Preferred stock, shares authorized                 1,500 1,500      
Preferred stock, shares issued                 787 787      
Preferred stock, shares outstanding                 787 787      
Convertible Preferred Stock: Series 2 [Member] | Maximum [Member] | Securities Purchase Agreement [Member]                            
Common stock were issued           1,500                
Common stock were issued value           $ 1,500,000                
Convertible Preferred Stock: Series 2 [Member] | 2020 Bridge Financing [Member] | Securities Purchase Agreement [Member]                            
Preferred stock, shares issued             713              
Stock issued during period conversion of convertible securities             1,426,849              
Convertible Preferred Stock: Series 2 [Member] | 2020 Bridge Financing [Member] | Chanticleer [Member] | Securities Purchase Agreement [Member]                            
Sale of stock, number of shares           1,500                
Gross proceeds preference stock           $ 1,500,000                
Sale of stock, transaction costs           $ 95,000                
Warrants term           5 years                
Warrants to purchase common stock           350,000                
Common stock, par value           $ 1.25                
Preferred stock value           $ 1,000                
Embedded derivative liability           529,000                
Beneficial conversion feature           $ 729,000                
Preferred Stock: Series 2 [Member] | 2020 Bridge Financing [Member]                            
Stock issued during period conversion of convertible securities                   1,400        
Preferred stock description                   The shareholders of Chanticleer common stock received shares of Amergent on a 1 for 1 basis (spin-off shares) and received 1 share of Sonnet common stock for 26 shares of Chanticleer common stock held at the time of the Merger.        
Common stock were issued value                   $ 1,250,000        
Percentage of cash equal to dollar value                   1.25%        
Trigger default interest rate                   18.00%        
Fair value of the derivative liability                 $ 529,000 $ 529,000        
Increase (decrease) in derivative liabilities                 $ 344,200          
Conversion price                 $ 1.00 $ 1.00        
Beneficial ownership percentage limitation                 4.99% 4.99%        
Percentage of limitation prior to merger                   9.99%        
Series 2 Preferred Stock [Member]                            
Preferred stock, shares outstanding                 787 787        
Cash payment to stock holders   $ 66,000                        
Number of warrants issued to purchase common stock   134,000 134,000                      
Common stock were issued value   $ 28,060